CEL-SCI Corporation (NYSE MKT:CVM) announced today that a new
video interview with Geert Kersten, Chief Executive Officer, is
available for viewing. This new video summarizes CEL-SCI’s Phase 3 head
and neck cancer trial progress and responds to questions about the
ongoing $50 million plus arbitration that CEL-SCI brought against its
former Clinical Research Organization (CRO). The arbitration hearing
(“trial”) has been scheduled to start in spring of 2016.
The interview was conducted at the Source Capital 2016 Disruptive Growth
& Healthcare Conference with Stock News Now and is available to view at https://www.youtube.com/watch?v=lQ8DnD6Uz3E
or on CEL-SCI’s website at www.cel-sci.com/investor_relations.html.
This new video is different from last week’s video in which Mr. Kersten
was a guest on Fox Business’ ‘Making Money with Charles Payne’. The
segment, which focused on finding a cure to cancer, aired on Wednesday,
February 17 between 6:00 and 7:00 p.m. ET. To view the segment, please
visit: http://video.foxbusiness.com/v/4761247378001/are-scientists-on-the-cusp-of-finding-a-cure-for-cancer/?#sp=show-clips
About CEL-SCI Corporation
CEL-SCI is a Phase 3 immunotherapy company with platform technologies
that can potentially treat a variety of cancers and viral diseases. We
believe that one must activate the immune system BEFORE radiation and
chemotherapy, and even before surgery, to achieve the best results in
the greatest number of patients. CEL-SCI is conducting a Phase 3 trial
in 24 countries of Multikine (Leukocyte Interleukin Injection) for the
treatment of head and neck cancer, which accounts for about 6% of
cancers globally and a $6 billion market. Almost 700 patients are
already enrolled in this study. CEL-SCI is also testing Multikine with
the U.S. Navy in HIV infected patients with HPV related diseases.
CEL-SCI has development partnerships with Teva Pharmaceuticals, Orient
EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its own
75,000 sq. ft. manufacturing facility and produces Multikine for its
clinical trials. When fully built out, this facility will have the
capacity to supply about $3 billion worth of Multikine annually. CEL-SCI
is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen
Presentation System) technology as a potential vaccine for the treatment
of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160223005703/en/
Copyright Business Wire 2016